Supporting the potential utility as an early marker of MF patients that will progress, which only occurs in a subset of patients, we found heterogeneous expression of RUNX2 in malignant T-cells between different patients at the early (I-II) stages as well as an inverse correlation with overall CTCL stage (Figure 3J). This evidence concerns the gene RUNX2 and mycosis fungoides.